Why did AELIS.PA stock spike today?

The intraday spike to **€2.20** was driven by heavy volume (**493,545.00**) and momentum trading. Market participants are pricing clinical progress and sector flows. No single official release explains all volume; monitor company and trial announcements.

What valuation metrics should I watch for AELIS.PA stock?

Focus on EPS **-0.60**, PE **-3.67** (loss-making), PB **4.92**, cash per share **€0.79**, and current ratio **3.18**. For biotechs, cash runway and trial milestones are more relevant than standard profit metrics.

What price targets and scenarios apply to AELIS.PA stock?

Meyka AI gives a conservative target **€1.66**, base **€2.80**, and bullish **€7.17**. These reflect different clinical and market outcomes and are model projections, not guarantees.

Should I trade AELIS.PA stock on this volume move?

High intraday volume creates short-term opportunity but also risk. Use tight risk controls, position sizing, and confirm with catalyst news. The stock is speculative and best sized small in portfolios.

EU Stocks

AELIS.PA stock jumps 13.99% intraday to €2.20 on heavy 493,545 volume: what traders should watch next

ByHuzaifa Zahoor January 29, 2026

AELIS.PA stock is the top high-volume mover on EURONEXT intraday after jumping 13.99% to €2.20 on 493,545.00 shares traded. The move follows a large spike in relative volume (relVolume 12.84) and pushes the price well above the 50-day average of €1.15. Traders are reacting to clinical progress signals and sector flows in European healthcare. We examine why volume matters now, how fundamentals and technicals line up, and what the Meyka AI model and market metrics say for short-term and medium-term scenarios.